TNFSF11 and osteonecrosis: Osteonecrosis occurs when bisphosphonate or RANKL inhibitors are administered in the presence of inflamed pulpal or periodontal tissue, because anti-resorptive agents affect the function of various immune cells, such as of neutrophils and polymorphonuclear leukocytes, macrophages, and dendritic cells33–38.